Drugs / DS-3201b
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04276662 | Nov 2019 → Feb 2021 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT03110354 | Apr 2017 → Mar 2021 | acute lymphoblastic leukemia, acute myeloid leukemia | Daiichi Sankyo | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02732275 | Mar 2016 → Dec 2022 overdue | non-Hodgkin lymphoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03879798 | Mar 2019 → May 2023 | small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-3201b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04276662 ↗ |
| Action | Inhibit | “a novel inhibitor of EZH2 and EZH1” PMID 39486432 ↗ Oct 2024 |
| Route | Oral | “DS-3201b administered orally to participants with AML or ALL.” NCT03110354 ↗ |
| Target | EZH1 | “a novel inhibitor of EZH2 and EZH1” PMID 39486432 ↗ Oct 2024 |
| Target | EZH2 | “a novel inhibitor of EZH2 and EZH1” PMID 39486432 ↗ Oct 2024 |